Cannabis Canada Weekly: Aurora CEO Seeks Capital Flexibility; Cronos to Launch Lab-Grown Cannabis Product

Article by David George-CoshBNN Bloomberg

MARIJUANA 51m ago Cannabis Canada Weekly: Aurora CEO seeks capital flexibility; Cronos to launch lab-grown pot product David George-Cosh, BNN Bloomberg An employee holds a tray of Aurora Cannabis Inc. Drift brand edibles inside the Hobo Cannabis Co. store in Ottawa, Ontario, Canada, on Thursday, Jan. 30, 2020. Bloomberg/David Kawai Aurora Cannabis says bought deal offers ‘maximum flexibility’ in U.S. push

Aurora Cannabis says bought deal offers ‘maximum flexibility’ in U.S. push

The time was right for Aurora Cannabis Inc. to strike with yet another bought deal last week. The cannabis company looked to take advantage of a recent run in its stock amid a broad investor move into cannabis at the beginning of the year.

The net result is an additional US$137 million in proceeds to Aurora’s balance sheet, albeit with some additional dilution to the company’s stock. While some shareholders may be growing tired of Aurora’s equity moves, the additional capital will give the company some more flexibility when looking south of the border for additional deals, its chief executive officer told BNN Bloomberg. One analyst estimated the move now gives Aurora roughly $700 million in capital to use for further investment.

“The reality is, right now is our current syndicate of financing has a risk tolerance as it pertains to us, that is probably a lot more conservative than maybe ours would be,” said Miguel Martin in a recent interview.

“We needed to put ourselves in a position where if something were to happen, particularly in the U.S., we could take them out and have maximum flexibility.”

What Aurora’s role in the U.S. cannabis market will be remains to be seen. The company does have some operations there through its acquisition of CBD retailer Reliva LLC, but Martin sees the company’s expertise in plant genetics and cultivation as a potential asset to deploy once it can operate in the U.S.

Martin points to Canopy Growth Corp.’s recent lawsuit against GW Pharmaceuticals PLC in the U.S. over CBD extraction methods as a pivotal moment that could help determine the value of what some cannabis genetics and intellectual property is worth.

“Companies like Aurora, or Canopy, have some of the deepest genetic libraries in the world,” he said. “Someone’s gonna look like [agricultural seed supplier] Monsanto. I’m not saying it’s us, but someone’s gonna look like Monsanto.”

But Martin adds that he thinks once the U.S. does legalize cannabis federally – something that might take longer than what some people have eagerly forecast – it’ll look a lot more regulated with the U.S. Food and Drug Administration borrowing the same playbook employed by Health Canada.

“I just think that people are a little bit naive if they don’t think it’s going to look a lot like Canada and a lot less like the Wild West when it comes to federal regulation of cannabis,” Martin said

Cronos on pace to launch lab-grown cannabis products this year 

Would you consume cannabis that was lab-grown? Cronos Group is betting that you will, as it plans to release its first lab-grown products that contain cannabinoids created using biosynthesis, an engineering process similar to brewing beer. That process could see Cronos make cannabis containing THC and CBD for pennies on the dollar. “We’re waiting on licensing, but one of our biggest initiatives for this year is making sure we can actually bring something to the market,” Cronos Executive Chairman Mike Gorenstein told BNN Bloomberg.   

Horizons lauches first ETF for psychedelic drug firms 

Horizons launched the world’s first exchange-traded fund for psychedelic-drug companies earlier this week. The ETF operator said its Psychedelic Stock Index ETF, listed as PSYK, began trading on the NEO Exchange on Wednesday, giving investors access to a stream of companies involved in prospective mental health treatments using the drugs. Some of the companies held in the ETF include MindMed and Peter Thiel-backed Compass Pathways. The fund will track the North American Psychedelics Index.  

Read the full article here.

About Dankr NewsBot

Beep Boop. I'm just a bot who brings you the dankest news in the biz

Leave a Reply

Powered by Dragonballsuper Youtube Download animeshow